Nabiximols Improve Spasticity Symptoms in Motor Neuron Disease

Share the love

From Neurology Advisor: Nabiximols, a cannabidiol, reduced spasticity symptoms and was tolerable and safe when used in patients with motor neuron disease, according to a phase 2 trial published in Lancet Neurology.

In this randomized, double-blind study (ClinicalTrials.gov identifier: NCT01776970), patients with possible, probable, or definite amyotrophic lateral sclerosis or primary lateral sclerosis were enrolled (N = 59). All patients presented with spasticity symptoms associated with motor neuron disease for ≥3 months and were taking an antispasticity therapy for 30 days before study entry. Researchers randomly assigned patients to either a standardized oromucosal spray composed of nabiximols and containing a combination of delta-9-tetrahydrocannabinol and cannabidiol (each 100 μL actuation composed of 2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol; n = 29) or placebo (n = 30) for a 6-week treatment period.

Continue Reading.

See the original report  in The Lancet.

Leave a Reply